Navigation Links
Study Assesses Blood Thinner Use After Gastrointestinal Bleeding
Date:9/17/2012

MONDAY, Sept. 17 (HealthDay News) -- New research suggests that people who stop taking the blood thinner warfarin (Coumadin) because of gastrointestinal bleeding raise their risk of blood clots and death if they stay off the drug.

The study, published online Sept. 17 in the Archives of Internal Medicine, is limited because it looks only at what happened to patients over a 90-day period after suffering from gastrointestinal bleeding. But the findings do point to the risk of staying off the blood thinner for a long period, said Dr. Amir Jaffer, professor of medicine and division chief for hospital medicine at the University of Miami and co-author of a commentary accompanying the study.

In general, Jaffer said, he recommends that patients who suffer from bleeding in the gastrointestinal tract stop taking the blood thinner for about four days unless a significant reason exists to avoid the drug for the long term. "That number [of days] will vary depending on the severity of the bleeding," he said, adding that physicians should provide the proper guidance.

The blood thinner is prescribed to prevent conditions such as stroke and heart attack by making it harder for clots to form and block the blood stream. The medications, however, raise the risk of blood vessels rupturing. About 4.5 percent of patients treated with the blood thinner have an episode of gastrointestinal tract bleeding, according to the researchers.

The study authors reviewed medical records of nearly 450 Colorado patients who developed gastrointestinal bleeding while taking warfarin. The participants' average age was 72.

Close to 60 percent were taking warfarin again within two to nine days of bleeding. Over 90 days, about 12 percent of patients died. After researchers adjusted their statistics so they wouldn't be skewed by factors such as gender or age, they found that those who resumed taking warfarin were 31 percent less likely to die than those who didn't. Fewer than 6 percent of those who resumed warfarin died, compared to 20 percent of those who didn't.

Of the 260 patients who resumed taking warfarin, only one suffered from a stroke or major blood clot, compared to 5.5 percent of those who stayed off the drug.

In the commentary, Jaffer and his co-author said the findings might not apply to newer blood thinners, such as dabigatran and rivaroxaban, which could have a greater risk of gastrointestinal bleeding than warfarin over time.

More information

For more about blood thinners, visit the U.S. National Library of Medicine.

-- Randy Dotinga

SOURCES: Amir Jaffer, M.D., associate professor, medicine, and division chief, hospital medicine, University of Miami Miller School of Medicine; Sept. 17, 2012, Archives of Internal Medicine


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Study Suggests Vaccine May Help Kids With Brain Cancer
2. Study reveals how cancer drug causes diabetic-like state
3. Coffee Drinking in Pregnancy Wont Lead to Sleepless Baby: Study
4. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
5. Veggies Like Broccoli, Cabbage May Help Fight Breast Cancer: Study
6. No Added Cancer Risk From Hip Replacement Materials: Study
7. Reported Decline in U.S. Pneumonia Deaths May Be False: Study
8. Early Study Finds Some Promise for Lung Cancer Vaccine
9. Narcissists Often Ace Job Interviews, Study Finds
10. Sexual objectification of female artists in music videos exists regardless of race, MU study finds
11. Soy may alleviate hot flashes in menopause, large-scale study finds
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study Assesses Blood Thinner Use After Gastrointestinal Bleeding
(Date:1/17/2017)... , ... January 17, 2017 , ... January is National Stalking Awareness Month ... to lurk in the corners and commit the crime of stalking, a very real danger ... addiction, an often overlooked factor in stalking and other crimes. , “Stalking: know it. Name ...
(Date:1/17/2017)... ... ... For breast cancer clinicians and researchers who were unable to attend the 2016 ... and analysis of its highlights, a novel half-day, complimentary meeting—the 14th Annual Best of ... 4, 2017 in Chicago. Chaired by Kathy S. Albain, MD, FACP, FASCO from the ...
(Date:1/17/2017)... ... January 17, 2017 , ... Kevin Harrington (one of the original Sharks ... DRTV campaigns regarding the topic of Beauty and Personal Care. , ... What better way to commit to these changes than beginning with personal care and ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... Mirror Mirror ... earned the highest honor of Diamond Level in Zeltiq’s Crystal Rewards Program. Practice founder, ... part of this elite group of providers. , Produced by Zeltiq, CoolSculpting is ...
(Date:1/17/2017)... ... ... A prescription medication bottle, pocket knife, luggage and a solar-powered aluminum casting process ... , the Cradle to Cradle Products Innovation Institute has announced. , This ... through early 2018. The challenges are presented by the Institute in partnership with Autodesk ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... 2017 In China , we ... the Upgrade of China,s Healthy Strategy ... Plan for Economic and Social Development of the ... and the state council of the People,s Republic ... emerging industry development plan, identifying medical devices as one of ...
(Date:1/18/2017)... Jan. 18, 2017  Tarix Orphan LLC today announced ... a Rare Pediatric Disease (RPD) designation for the company,s ... Epidermolysis Bullosa (RDEB), a rare genetic skin disorder. There ... is limited to supportive care. "The RPD ... Designation previously granted by the FDA in this indication," ...
(Date:1/18/2017)...  Robust competition in the private marketplace is resulting in ... to a new study by the Berkeley ... to examine the share of prescription medicine spending retained ... health plans and other stakeholders in the supply chain. ... show what happens when the list price of a ...
Breaking Medicine Technology: